Author Interviews, COVID -19 Coronavirus, Pharmaceutical Companies, Vaccine Studies / 17.03.2020
Plant-Based Coronavirus Vaccine Candidate Developed by Medicago
MedicalResearch.com Interview with:
[caption id="attachment_53541" align="alignleft" width="180"]
Dr. Machelska[/caption]
Nathalie Charland PhD
Senior Director, Scientific and Medical Affairs
Medicago
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: We started to work on solutions as soon as we were able to obtain the appropriate genetic information for the new COVID-19. Medicago is committed to advancing therapeutics against life-threatening diseases worldwide.
Dr. Machelska[/caption]
Nathalie Charland PhD
Senior Director, Scientific and Medical Affairs
Medicago
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: We started to work on solutions as soon as we were able to obtain the appropriate genetic information for the new COVID-19. Medicago is committed to advancing therapeutics against life-threatening diseases worldwide.
Dr. Kooraki[/caption]
Soheil Kooraki MSR MS, MD
on behalf of Dr. Ali Gholamrezanezhad MD and co-authors
Department of Radiological Sciences,
David Geffen School of Medicine, University of California at Los Angeles
Los Angeles, California
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: COVID19 is a novel strain of the coronavirus family causing pneumonia. Two similar strains were discovered in 2003 and 2012 to cause the so-called SARS and MERS outbreaks, respectively. Radiologists need to be prepared for the escalating incidence of COVID-19. We reviewed the literature to extract the epidemiologic and imaging features of SARS and MERS in comparison with known imaging features of COVID-19 pneumonia to have a better understanding of the imaging features of the COVID19 pneumonia in acute and post-recovery stages.
